Janux Therapeutics (JANX) Common Equity (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Common Equity of $941.5 million for Q1 2026, down 7.01% year-over-year from $1.0 billion in Q1 2025, and down 1.6% quarter-over-quarter from $956.8 million in Q4 2025.
Janux Therapeutics (JANX) Common Equity (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Common Equity for 7 consecutive years, with $941.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 7.01% year-over-year to $941.5 million; the TTM figure through Mar 2026 stood at $941.5 million (down 7.01% YoY), while the FY2025 annual figure was $956.8 million, down 6.45% from the prior year.
- Common Equity eased to $941.5 million in Q1 2026 per JANX's latest filing, from $956.8 million in the prior quarter.
- Across five years, Common Equity topped out at $1.0 billion in Q4 2024 and bottomed at $299.5 million in Q2 2023.
- Historically, Common Equity has averaged $619.2 million across 5 years, with a median of $655.8 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 2223.2% — and 2023, when it slipped 12.9%.
- Janux Therapeutics' Common Equity stood at $320.7 million in 2022, then rose by 7.36% to $344.3 million in 2023, then soared by 197.02% to $1.0 billion in 2024, then dropped by 6.45% to $956.8 million in 2025, then declined by 1.6% to $941.5 million in 2026.
- Business Quant data shows JANX's Common Equity at $941.5 million in Q1 2026, $956.8 million in Q4 2025, and $976.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 927.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 927.98 Mn |
| Mar 31, 2026 | 941.54 Mn |
| Dec 31, 2025 | 956.82 Mn |
| Sep 30, 2025 | 976.56 Mn |
| Jun 30, 2025 | 990.52 Mn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 1.02 Bn |
| Sep 30, 2024 | 656.10 Mn |
| Jun 30, 2024 | 657.68 Mn |
| Mar 31, 2024 | 655.76 Mn |
| Dec 31, 2023 | 344.35 Mn |
| Sep 30, 2023 | 348.95 Mn |
| Jun 30, 2023 | 299.47 Mn |
| Mar 31, 2023 | 311.26 Mn |
| Dec 31, 2022 | 320.74 Mn |
| Sep 30, 2022 | 331.51 Mn |
| Jun 30, 2022 | 343.81 Mn |
| Mar 31, 2022 | 356.08 Mn |
| Dec 31, 2021 | 366.33 Mn |
| Sep 30, 2021 | 376.75 Mn |